BIOMAT Database Logo BIOMAT Database Logo

Expression of the multidrug transporter, P-glycoprotein, in chronic myelogenous leukaemia cells in blast crisis. 1990

Y Kuwazuru, and A Yoshimura, and S Hanada, and M Ichikawa, and T Saito, and K Uozumi, and A Utsunomiya, and T Arima, and S Akiyama
Cancer Research Institute, Faculty of Medicine, Kagoshima University, Japan.

The overexpression of a cell-surface glycoprotein termed P-glycoprotein (P-gp) is frequently associated with multidrug resistance (MDR) in cell lines in vitro. To evaluate the implications of P-gp expression in clinical drug-resistance, we examined the expression of P-gp in fresh leukaemia cells from chronic myelogenous leukaemia (CML) patients in blast crisis. By using immunoblotting with a monoclonal antibody against P-gp, C219, we showed that leukaemia cells from three CML patients in blast crisis were P-gp negative at the stage when these patients were in complete remission, and that the cells showed high levels of P-gp expression at times when the same patients had relapsed and had not responded to chemotherapy. Six out of 11 patients (nine in the refractory state) were P-gp positive and they rarely responded to chemotherapy. These data suggest that the expression of P-gp is closely associated with drug-resistance in CML.

UI MeSH Term Description Entries
D008297 Male Males
D008562 Membrane Glycoproteins Glycoproteins found on the membrane or surface of cells. Cell Surface Glycoproteins,Surface Glycoproteins,Cell Surface Glycoprotein,Membrane Glycoprotein,Surface Glycoprotein,Glycoprotein, Cell Surface,Glycoprotein, Membrane,Glycoprotein, Surface,Glycoproteins, Cell Surface,Glycoproteins, Membrane,Glycoproteins, Surface,Surface Glycoprotein, Cell,Surface Glycoproteins, Cell
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009363 Neoplasm Proteins Proteins whose abnormal expression (gain or loss) are associated with the development, growth, or progression of NEOPLASMS. Some neoplasm proteins are tumor antigens (ANTIGENS, NEOPLASM), i.e. they induce an immune reaction to their tumor. Many neoplasm proteins have been characterized and are used as tumor markers (BIOMARKERS, TUMOR) when they are detectable in cells and body fluids as monitors for the presence or growth of tumors. Abnormal expression of ONCOGENE PROTEINS is involved in neoplastic transformation, whereas the loss of expression of TUMOR SUPPRESSOR PROTEINS is involved with the loss of growth control and progression of the neoplasm. Proteins, Neoplasm
D001752 Blast Crisis An advanced phase of chronic myelogenous leukemia, characterized by a rapid increase in the proportion of immature white blood cells (blasts) in the blood and bone marrow to greater than 30%. Blast Phase,Blast Crises,Blast Phases,Crises, Blast,Crisis, Blast,Phase, Blast,Phases, Blast
D004351 Drug Resistance Diminished or failed response of an organism, disease or tissue to the intended effectiveness of a chemical or drug. It should be differentiated from DRUG TOLERANCE which is the progressive diminution of the susceptibility of a human or animal to the effects of a drug, as a result of continued administration. Resistance, Drug
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000971 Antineoplastic Combined Chemotherapy Protocols The use of two or more chemicals simultaneously or sequentially in the drug therapy of neoplasms. The drugs need not be in the same dosage form. Anticancer Drug Combinations,Antineoplastic Agents, Combined,Antineoplastic Chemotherapy Protocols,Antineoplastic Drug Combinations,Cancer Chemotherapy Protocols,Chemotherapy Protocols, Antineoplastic,Drug Combinations, Antineoplastic,Antineoplastic Combined Chemotherapy Regimens,Combined Antineoplastic Agents,Agent, Combined Antineoplastic,Agents, Combined Antineoplastic,Anticancer Drug Combination,Antineoplastic Agent, Combined,Antineoplastic Chemotherapy Protocol,Antineoplastic Drug Combination,Cancer Chemotherapy Protocol,Chemotherapy Protocol, Antineoplastic,Chemotherapy Protocol, Cancer,Chemotherapy Protocols, Cancer,Combinations, Antineoplastic Drug,Combined Antineoplastic Agent,Drug Combination, Anticancer,Drug Combination, Antineoplastic,Drug Combinations, Anticancer,Protocol, Antineoplastic Chemotherapy,Protocol, Cancer Chemotherapy,Protocols, Antineoplastic Chemotherapy,Protocols, Cancer Chemotherapy

Related Publications

Y Kuwazuru, and A Yoshimura, and S Hanada, and M Ichikawa, and T Saito, and K Uozumi, and A Utsunomiya, and T Arima, and S Akiyama
Extramedullary blast crisis in chronic myelogenous leukaemia.
June 1990, The Journal of the Association of Physicians of India,
Y Kuwazuru, and A Yoshimura, and S Hanada, and M Ichikawa, and T Saito, and K Uozumi, and A Utsunomiya, and T Arima, and S Akiyama
Emperipolesis observed in immature cells in blast crisis of chronic myelogenous leukaemia.
February 1981, Scandinavian journal of haematology,
Y Kuwazuru, and A Yoshimura, and S Hanada, and M Ichikawa, and T Saito, and K Uozumi, and A Utsunomiya, and T Arima, and S Akiyama
Hand-mirror cell blast-crisis of chronic myelogenous leukaemia.
July 1985, Scandinavian journal of haematology,
Y Kuwazuru, and A Yoshimura, and S Hanada, and M Ichikawa, and T Saito, and K Uozumi, and A Utsunomiya, and T Arima, and S Akiyama
Extramedullary presentation of the blast crisis of chronic myelogenous leukaemia.
October 1985, British journal of haematology,
Y Kuwazuru, and A Yoshimura, and S Hanada, and M Ichikawa, and T Saito, and K Uozumi, and A Utsunomiya, and T Arima, and S Akiyama
Expression of a multidrug resistance gene in blast crisis of chronic myelogenous leukemia.
January 1989, Cancer communications,
Y Kuwazuru, and A Yoshimura, and S Hanada, and M Ichikawa, and T Saito, and K Uozumi, and A Utsunomiya, and T Arima, and S Akiyama
Lymphoid blast crisis at the onset of chronic myelogenous leukaemia: molecular evidence.
July 1994, British journal of haematology,
Y Kuwazuru, and A Yoshimura, and S Hanada, and M Ichikawa, and T Saito, and K Uozumi, and A Utsunomiya, and T Arima, and S Akiyama
p-190 chronic myelogenous leukemia presenting as extramedullary blast crisis.
January 2015, Indian journal of cancer,
Y Kuwazuru, and A Yoshimura, and S Hanada, and M Ichikawa, and T Saito, and K Uozumi, and A Utsunomiya, and T Arima, and S Akiyama
Recurrent localised extramedullary blast crisis in a patient with chronic myelogenous leukaemia.
September 1988, The New Zealand medical journal,
Y Kuwazuru, and A Yoshimura, and S Hanada, and M Ichikawa, and T Saito, and K Uozumi, and A Utsunomiya, and T Arima, and S Akiyama
Immunophenotypic, genomic and clinical characteristics of blast crisis of chronic myelogenous leukaemia.
November 1991, British journal of haematology,
Y Kuwazuru, and A Yoshimura, and S Hanada, and M Ichikawa, and T Saito, and K Uozumi, and A Utsunomiya, and T Arima, and S Akiyama
The P-glycoprotein multidrug transporter.
September 2011, Essays in biochemistry,
Copied contents to your clipboard!